Brodimoprim, a new bacterial dihydrofolate reductase inhibitor: a minireview.
This brief review article synthesizes the principal literature regarding the clinical status of co-trimoxazole compared to monotherapy with one of the two diaminopyrimidines available commercially: trimethoprim or brodimoprim. Both these inhibitors of bacterial dihydrofolate reductase compare favorably to co-trimoxazole as antimicrobial chemotherapy. Brodimoprim is characterized by its advantageous pharmacokinetics in comparison to both co-trimoxazole and trimethoprim.
Periti
P
P
Department of Preclinical and Clinical Pharmacology, University of Florence, Firenze, Italy.
D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use; D004341:Drug Evaluation; D005493:Folic Acid Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D013762:Tetrahydrofolate Dehydrogenase / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use; D014295:Trimethoprim / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D005493:Folic Acid Antagonists; D014295:Trimethoprim; D013762:Tetrahydrofolate Dehydrogenase; C037079:brodimoprim